Showing 1361-1370 of 1560 results for "".
- Amidst the COVID-19 Pandemic, Early Intervention Remains an Obstacle for Overall Eye Health Despite Fear of Blindnesshttps://modernod.com/news/amidst-the-covid-19-pandemic-early-intervention-remains-an-obstacle-for-overall-eye-health-despite-fear-of-blindness/2480352/Globally, most adults, 70 percent, don’t plan to get their eyes examined this year, despite acknowledging the critical importance of eye health. These new findings come from a comprehensive, large-scale Johnson & Johnson Vision Global Eye Health Survey announced in advance of World Sigh
- J&J Vision Announces New Collaboration Aimed at Eliminating Inequities in the Eye Care Industryhttps://modernod.com/news/johnson-johnson-vision-announces-new-collaboration-aimed-at-eliminating-inequities-in-the-eye-care-industry/2480280/Johnson & Johnson Vision announced a collaboration with
- Market Scope: Phaco and FLACS Upgrades to Drive Expansion in Cataract Equipment Markethttps://modernod.com/news/market-scope-phaco-and-flacs-upgrades-to-drive-expansion-in-cataract-equipment-market/2479462/A number of market leaders in phaco and femtosecond cataract technology will launch upgraded platforms over the next year, which is expected to increase market penetration for both types of systems and stimulate the replacement of older models. Johnson & Johnson Vision has introduced i
- Study Shows Reduction in Postoperative Halos in Patients Treated With Tearscience Lipiflow Treatment Prior to Bilaterial Cataract Surgeryhttps://modernod.com/news/study-shows-reduction-in-postoperative-halosin-patients-treated-with-tearscience-lipiflow-treatment-prior-to-bilaterial-cataract-surgery/2479413/Johnson & Johnson Vision revealed new comparative clinical study findings evaluating TearScience LipiFlow treatment in cataract surgery. The data concluded that treating patients with TearScience LipiFlow prior to cataract surgery significantly reduced patient-reports of halos compared to con
- J&J Vision Launches Tecnis Eyhance Toric II IOL with Tecnis Simplicity Delivery System in Europehttps://modernod.com/news/jj-vision-announces-launch-of-tecnis-eyhance-toric-ii-iol-with-tecnis-simplicity-delivery-system-in-europe/2479274/Johnson & Johnson Vision announced the launch and availability of its Tecnis Eyhance Toric II IOL with Tecnis Simplicity Delivery System for the treatment of cataracts patients with astigmatism in Europe. This monofocal lens allows for high-quality vision at both intermediate and far distance
- At-Home App Helps Patients Stay Engaged and Adherent to Vision Monitoring Remotelyhttps://modernod.com/news/at-home-app-helps-patients-stay-engaged-and-adherent-to-vision-monitoring-remotely/2479208/Novartis announced it has begun a US pilot program for OdySight, a clinically tested mobile application designed to help monitor vision remotely. Recent changes to public health protocols, paired with a growing patient population and existing treatment burden, have placed an emphasis on vi
- J&J Vision Announces Collaboration with Menicon to Bring Forward Contact Lenses for Childrenhttps://modernod.com/news/jj-vision-announces-collaboration-with-menicon-to-bring-forward-contact-lenses-for-children/2479057/Johnson & Johnson Vision announced a global strategic collaboration with Menicon, a manufacturer of contact lenses. As part of the collaboration, Menicon will develop and manufacture the contact lenses to help manage the progression of myopia in children. Johnson & Johnson Vision will foc
- J&J’s Coronavirus Vaccine Garners WHO Emergency-Use Listinghttps://modernod.com/news/jjs-coronavirus-vaccine-garners-who-emergency-use-listing/2478968/Johnson & Johnson said that the World Health Organization (WHO) has issued an emergency-use listing for its single-dose coronavirus vaccine Ad26.COV2.S to prevent COVID-19 in people 18 years and older. Chief scientific officer Paul Stoffels stated that “achieving this important prerequi
- EU Greenlights J&J’s Coronavirus Vaccinehttps://modernod.com/news/eu-greenlights-jjs-coronavirus-vaccine/2478966/The European Commission granted a conditional marketing authorization for Johnson & Johnson’s single-dose COVID-19 vaccine Ad26.COV2.S in people 18 years of age and over. The decision comes just hours after the European Medicines Agency (EMA) gave its backing following a review of ̶
- J&J’s COVID-19 Vaccine Wins FDA Authorization for Emergency Usehttps://modernod.com/news/jjs-covid-19-vaccine-wins-fda-authorization-for-emergency-use/2478921/The US has added a third option to its arsenal of COVID-19 vaccines after the FDA authorized Johnson & Johnson’s single-dose candidate Ad26.COV2.S for emergency use in people 18 years and older on Saturday. Peter Marks, director of the FDA’s Center for Biologics Evaluation a